The Laguna Hills-based device maker of a system that treats cardiac arrhythmias reported that net loss widened from $3.9 million to $6.7 million during the same quarter a year ago. Additionally, Adagio posted no revenue due to a pause in commercial activity in Europe, according to the company. Adagio’s stock fell 5% to 68 cents apiece and a $15 million market cap (Nasdaq: ADGM).